Korro Bio, Inc. (KRRO) Financial Analysis & Valuation | Quarter Chart
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medici... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $105.31M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ram Aiyar |
| IPO Date | 2019-10-03 | CAGR | — |
| Employees | 57 | Website | www.korrobio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KRRO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $226.68M | P/E | -1.06 | Forward P/E | -2.37 | PEG | — |
| P/S | 1.61 | P/B | 0.07 | P/CF | -0.08 | P/FCF | -0.05 |
| Sales | $2.38M | Sales 1Y | -62.08% | Sales 3Y | inf% | Sales 5Y | -93.25% |
| EPS | $-10 | EPS 1Y | 2.67% | EPS 3Y | -19.73% | EPS 5Y | -87.3% |
| Sales QoQ | — | EPS QoQ | -36.69% | Sales QoQ Avg | — | EPS QoQ Avg | 10.67% |
| Gross Margin | 56.8% | Operating Margin | -3176.57% | Profit Margin | -4477.08% | ROCE | -50.17% |
| ROA | -65% | ROE | -114% | Altman Z Score | -3.31 | Piotroski Score | 2 |
| Current Ratio | 9.55 | Quick Ratio | 9.55 | Cash Ratio | 1.97 | Op. CF Ratio | -2.62 |
| Debt/Equity | 0.41 | Debt/Assets | 0.26 | Lt Debt/Equity | 0.38 | Lt Debt/Cap. | 0.28 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $226.68M | P/E Ratio | -1.06 |
| Forward P/E | -2.37 | PEG Ratio | — |
| P/S Ratio | 1.61 | P/B Ratio | 0.07 |
| P/CF Ratio | -0.08 | P/FCF Ratio | -0.05 |
| EPS | $-10 | EPS Growth 1Y | 2.67% |
| EPS Growth 3Y | -19.73% | EPS Growth 5Y | -87.3% |
| Revenue Growth 1Y | -62.08% | Gross Margin | 56.8% |
| Operating Margin | -3176.57% | Profit Margin | -4477.08% |
| ROE | -114% | ROA | -65% |
| ROCE | -50.17% | Current Ratio | 9.55 |
| Quick Ratio | 9.55 | Cash Ratio | 1.97 |
| Debt/Equity | 0.41 | Interest Coverage | — |
| Altman Z Score | -3.31 | Piotroski Score | 2 |
Korro Bio, Inc. (KRRO) valuation & financials
Korro Bio, Inc. (KRRO) has a market capitalization of $105.31M and trades at a price-to-earnings ratio of -1.1. It operates in the Healthcare sector (Biotechnology).
Korro Bio, Inc.'s revenue grew -62.1% over the last year.
Korro Bio, Inc.'s next earnings report is scheduled for November 11, 2026 before market open (provider scheduled date); analysts estimate EPS of $-1.26. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)